Css LLC Clovis Oncology, Inc. Call Options Transaction History

Css LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $18,018 - $39,564	-12,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $40,160 - $56,400	8,000 Added 173.91%	12,600 $73,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $13,195 - $38,500	-3,500 Reduced 43.21%	4,600 $29,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $50,700 - $277,667	-16,900 Reduced 67.6%	8,100 $84,000
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $47,160 - $184,200	12,000 Added 92.31%	25,000 $98,000
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $176,600 - $302,800	10,000 Added 333.33%	13,000 $322,000
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $58,150 - $163,350	-5,000 Reduced 62.5%	3,000 $54,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $176,220 - $296,880	6,000 Added 300.0%	8,000 $235,000
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $231,330 - $343,200	-5,500 Reduced 73.33%	2,000 $91,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $967,316 - $1.31 Million	-19,300 Reduced 72.01%	7,500 $396,000
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $74,997 - $109,954	1,300 Added 5.1%	26,800 $1.82 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $1.71 Million - $2.16 Million	25,500	25,500 $2.1 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.